All Articles tagged chemotherapy

• Oncology
  October 27, 2023 EDT
  Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States
  Robert L. ColemanJamie GarsideJean HurteauJoehl NguyenMonica Kobayashi

  We describe real-world demographics, clinical characteristics, treatment patterns, and overall survival among US patients with primary advanced or recurrent endometrial cancer who initiated at least 1 line of therapy.

  Abstract
• Oncology
  September 08, 2023 EDT
  Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm
  Scott GouldenQin ShenRobert L. ColemanCara MathewsMatthias HungerAnkit PahwaRene Schade

  This study compared overall survival and described time-to-treatment discontinuation for dostarlimab (GARNET Cohort A1 safety population) with an equivalent real-world external control arm receiving non-anti-programmed death (PD)-1/PD-ligand 1/2 treatments.

  Abstract
• Oncology
  May 20, 2020 EDT
  Re-challenge of Platinum-based Chemotherapy for Platinum-refractory Patients with Recurrent or Metastatic Head and Neck Cancer: Claims Data Analysis in Japan
  Makoto TaharaIssei DoiTatsunori MurataSari MishinaShinji TakaiHirokazu Kaneko

  We assess the real-world treatment patterns and usefulness of platinum rechallenge in patients with platinum-refractory recurrent or metastatic head and neck cancer receiving platinum rechallenge.

  Abstract
• Oncology
  October 26, 2016 EDT
  A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
  Margaret HuxDenise ZouEsprit MaPeter SajosiAndreas EngstromRoss SelbyEugene BensonAndrew BriggsVijayveer Bonthapally

  To evaluate the cost-effectiveness of brentuximab vedotin in patients with R/R sALCL from a UK NHS perspective.

  Abstract
• Oncology
  November 16, 2015 EDT
  Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
  November McGarveyHairong Xu

  Anemia is a common complication among patients with cancer receiving chemotherapy and can cause significant costs to health plans.

  Abstract